Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | ORIGIN ENERGY LIMITED: Ceasing to be a substantial holder | - | ASX | ||
Di | Origin Energy: March Quarter Australia Pacific LNG Revenue Down 8% | 241 | AFX News | CANBERA (dpa-AFX) - Origin Energy Limited (ORG.AX, OGFGF.PK) reported that its Australia Pacific LNG revenue for the March quarter was 8 percent lower than the prior year, at A$2.553 billion.Quarterly... ► Artikel lesen | |
Di | Origin Energy's stake in Octopus Energy | 3 | Finance News Network | ||
Di | Australia's Origin Energy posts 7% sequential rise in APLNG revenue | 3 | Reuters | ||
Di | ORIGIN ENERGY LIMITED: March 2024 Quarterly Report | 2 | ASX | ||
Mo | ORIGIN ENERGY LIMITED: Becoming a substantial holder | - | ASX | ||
25.04. | ORIGIN ENERGY LIMITED: Ceasing to be a substantial holder | - | ASX | ||
24.04. | ORIGIN ENERGY LIMITED: Becoming a substantial holder | - | ASX | ||
22.04. | ORIGIN ENERGY LIMITED: Ceasing to be a substantial holder | - | ASX | ||
19.04. | ORIGIN ENERGY LIMITED: Appendix 3Y | - | ASX | ||
18.04. | ORIGIN ENERGY LIMITED: Becoming a substantial holder | - | ASX | ||
12.04. | Origin Energy hits 5-1/2 year high on Yanco Delta Wind Farm buy | 4 | Reuters | ||
12.04. | Origin Energy expands clean power portfolio with $300m Yanco Delta wind farm acquisition | 2 | smallcaps.com.au | ||
11.04. | ORIGIN ENERGY LIMITED: Origin acquires 1.5GW Yanco Delta wind development in NSW | 1 | ASX | ||
11.04. | Origin Energy appoints CFO: Australia's Origin Energy said on Thursday it had appointed company executive ... | - | Mining Weekly | ||
11.04. | ORIGIN ENERGY LIMITED: Notification of cessation of securities - ORG | - | ASX | ||
11.04. | ORIGIN ENERGY LIMITED: Notification regarding unquoted securities - ORG | - | ASX | ||
11.04. | ORIGIN ENERGY LIMITED: Notification regarding unquoted securities - ORG | - | ASX | ||
11.04. | Australia's Origin Energy appoints Tony Lucas as CFO | - | Reuters | ||
10.04. | ORIGIN ENERGY LIMITED: Appointment of new Chief Financial Officer | - | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PROCEPT BIOROBOTICS | 60,61 | 0,00 % | Earnings call: PROCEPT BioRobotics sees 83% revenue surge in Q1 2024 | ||
SIEMENS HEALTHINEERS | 51,28 | -1,57 % | EQS-DD: Siemens Healthineers AG: Dr. Bernhard Montag, Kauf von Siemens Healthineers Aktien für einen Betrag von EUR 98.817,91 abzüglich Steuern und Abgaben als automatische Wiederanlage von ... | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.04.2024 / 14:49... ► Artikel lesen | |
FRESENIUS | 28,170 | +0,72 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Fresenius vor Quartalszahlen von 41 auf 40 Euro gesenkt und die Einstufung auf "Buy" belassen. Ein zunächst vorsichtiger... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 40,410 | +2,05 % | Aixtron, FMC, LPKF Laser, ProSiebenSat.1 Media, Siemens Energy, Varta und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
ATRICURE | 24,810 | 0,00 % | AtriCure Reports First Quarter 2024 Financial Results | MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and... ► Artikel lesen | |
GENEDX | 20,880 | 0,00 % | Pre-market Movers: Cyclacel Pharmaceuticals, Marin Software, GeneDx, Sensata Technologies, Lichen China | INDIANAPOLIS (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.05 A.M. ET).In the Green Cyclacel Pharmaceuticals, Inc. (CYCC) is up... ► Artikel lesen | |
CARL ZEISS MEDITEC | 98,30 | -0,81 % | Neue 11,00% Aktienanleihe mit Barriere auf Carl Zeiss Meditec in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VD4NFC9/ WKN VD4NFC) mit Barriere auf die Aktie von Carl Zeiss... ► Artikel lesen | |
ADAPTHEALTH | 10,060 | 0,00 % | AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2023 Results and Provides Initial 2024 Outlook | PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including... ► Artikel lesen | |
RXSIGHT | 56,73 | 0,00 % | RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | ALISO VIEJO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery... ► Artikel lesen | |
MIMEDX | 7,300 | 0,00 % | MiMedx Group, Inc: MIMEDX Announces First Quarter 2024 Operating and Financial Results | Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management... ► Artikel lesen | |
PRIVIA HEALTH GROUP | 18,000 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results | Achieved All 2023 Operating and Financial Guidance MetricsImplemented Providers +19.4% compared to Year-End 2022Introduces Full-Year 2024 GuidanceProactive Steps to Limit Downside Risk Arrangements... ► Artikel lesen | |
GERRESHEIMER | 102,80 | +1,78 % | Gerresheimer schließt Partnerschaft mit RxCap für vernetzte Adhärenz-Lösungen | Düsseldorf/Berlin/Ohio, USA (ots) - Gerresheimer schließt Partnerschaft mit RxCap für vernetzte Adhärenz-Lösungen- Gerresheimer-Tochter Centor erhält exklusive Vertriebsrechte für Apotheken in den USA-... ► Artikel lesen | |
DOCGO | 3,390 | 0,00 % | Evaluating DocGo: Insights From 8 Financial Analysts | ||
CASTLE BIOSCIENCES | 22,060 | 0,00 % | Castle Biosciences Inc.: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer | If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes... ► Artikel lesen |